Development of antibiotic resistance · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cure: successful eradication of the infection · patients on maintenance HD with CRBSI
It is very uncertain whether systemic antibiotics alone changes cure: successful eradication of the infection compared with systematic antibiotics plus antibiotic lock solution (very low certainty).
1 finding from 1 review
Stenosis or thrombosis of vascular access site after catheter removal · patients on maintenance HD with CRBSI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response at 8 weeks · Patients with active or quiescent lymphocytic colitis
Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).
1 finding from 1 review
Maintenance of clinical response · Patients with active or quiescent lymphocytic colitis
It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).
1 finding from 1 review
Quitline referral vs control · smoking cessation in hospitalised patients
It is very uncertain whether telephone quitline referral changes quitline referral vs control compared with no treatment or usual care (very low certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in primary outcome: complete clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Observed number of pregnancies (all women) · women seeking emergency contraception
Low‐dose mifepristone (< 25 mg) leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (high certainty).
1 finding from 1 review
Side effects · women seeking emergency contraception
Low‐dose mifepristone (< 25 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review
Nausea · women seeking emergency contraception
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (moderate certainty).
1 finding from 1 review
Vomiting · women seeking emergency contraception
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ vomiting compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review
Specific side effects ‐ spotting/bleeding after treatment · women seeking emergency contraception
Low‐dose mifepristone (< 25 mg) leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (high certainty).
1 finding from 1 review
Menses ‐ early · women seeking emergency contraception
Low‐dose mifepristone (< 25 mg) may leads to lower menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review